Sanofi and Regeneron's 'blow-out' drug data for smoker's lung leads to stock surge.

Sanofi's asthma drug Dupixent, developed with Regeneron, has met all targets in a late-stage clinical trial to treat "smoker's lung" or chronic obstructive pulmonary disease (COPD), potentially adding billions to the French drugmaker's growth prospects. The drug led to a 30% reduction in moderate or severe acute exacerbations of COPD, and also showed improvements in lung function, quality of life, and respiratory symptoms. Analysts predict that the market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros.